Accelerating Product Excellence in Innovation and for Clinical Adoption (APEx) (U24 Clinical Trial Not Allowed)
NIH cooperative agreements fund multidisciplinary resource centers and linked translational projects to validate, manufacture, and preclinically test tissue engineering and regenerative medicine products for future first-in-human clinical studies.
⚑ U24 cooperative agreement; clinical trials not allowed · Foreign organizations, non-domestic components, and foreign components are not allowed · Focus is TE/RM products including therapeutics, sensors, and diagnostics · Emphasis on preclinical validation, manufacturing, regulatory support, and commercialization support
Unit fits — one characterization, each unit's own rules
| Physical Sciences & Engineering (demo) | 90 strong | technical depth: central; funds applied research |
| IPPRA | 45 partial | peripheral portfolio topic: public_health; social/behavioral work is none; funds applied research; biomedical core — IPPRA health lane is communication/crisis/policy (capped); capped at 45 (limited social-science role) |
| Tom Love Innovation Hub | 45 partial | funds applied research; prototyping/demonstration stage; deep-tech content |
Description
This Notice of Funding Opportunity (NOFO) solicits cooperative agreement research applications to support a multidisciplinary program titled "Accelerating Product Excellence in Innovation and for Clinical Adoption" (APEx), that will facilitate advancement of promising strategies and products for tissue engineering and regenerative medicine (TE/RM). APEx will be composed of Resource Centers (RCs) and associated Interdisciplinary Translational Projects (ITPs) in the area of therapeutics (including adult stem cell-based treatments), sensors, and diagnostics. RCs will capitalize on their available clinical, scientific, industrial, regulatory and commercialization expertise, to deliver technical support, research capacity, administrative infrastructure and regulatory and commercialization support to the ITPs and guide them to complete pre-clinical studies toward initiation of clinical trials. During this funding cycle, APEx will complete validation, manufacturing, and preclinical testing of the most promising products, which may include, but are not limited to products for detecting or treating tissue damage caused by congenital defect, traumatic injury, or chronic disease. Products that support early detection of chronic pathologies, monitoring of validated biomarkers of health or disease, as well as approaches to reduce or prevent resulting damage, are especially encouraged. The outcome of APEx will be TE/RM products with their regulatory approvals in place for first-in-human studies, along with associated clinical study protocols, and synthesis and manufacturing protocols ready for initiation of clinical trials.
Eligibility
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/Foreign CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Apply
View on Grants.gov → CONTACT: National Institutes of Health <APEx-NOFO@nih.gov>
Proposal brief SEE AN EXAMPLE →
A one-page internal memo: fit assessment, submission requirements, document scaffold, and next steps dated back from the deadline — tailored to your project idea if you add one.
Proposal shell · National Institutes of Health conventions SEE AN NIH EXAMPLE →
Funder-faithful document skeletons — National Institutes of Health's document set with section headings, page limits, reviewer guidance, and writing prompts; add a project idea to get [DRAFT] starter bullets. Download as .md for Word or Overleaf.
Legacy IPPRA LLM assessment (v2.0, for comparison)
15/100 · gpt-5.4-mini · 2026-07-06
This is primarily a translational biomedical and product-development cooperative agreement for tissue engineering/regenerative medicine, focused on preclinical validation, manufacturing, and regulatory readiness rather than social/behavioral/policy research. IPPRA’s strengths in health communication, survey research, and behavioral intervention are not central here, and public universities may participate only as eligible U.S. applicants or partners, so the fit is limited.
Legacy scoring history
| 2026-07-06 | 15 | gpt-5.4-mini | This is primarily a translational biomedical and product-development cooperative agreement for tissue engineering/regenerative medicine, focused on preclinical validation, manufacturing, and regulatory readiness rather than social/behavioral/policy research. IPPRA’s strengths in health communication, survey research, and behavioral intervention are not central here, and public universities may participate only as eligible U.S. applicants or partners, so the fit is limited. |
| 2026-07-06 | 8 | gpt-5.4-mini | This is a predominantly biomedical translational engineering opportunity focused on tissue engineering, regenerative medicine, and preclinical validation for clinical adoption. It does not materially engage IPPRA’s core strengths in human behavior, policy, risk communication, community resilience, or survey-based social science, and no clear portfolio-area social/policy component is evident. Public U.S. universities appear eligible in principle, but the topical fit is too remote for IPPRA. |